

Table S1. List of genes included in each category

Category 1: genetic variants that have been approved for treatment with the MC4R agonist setmelanotide in Europe, as well as those under investigation for setmelanotide efficacy in clinical trials.		
<i>BBS1</i>	<i>BBS20 (IFT172)</i>	<i>PHIP</i>
<i>BBS2</i>	<i>BBS21 (CFAP418)</i>	<i>PLXNA1</i>
<i>BBS3 (ARL6)</i>	<i>BBS22 (IFT74)</i>	<i>PLXNA2</i>
<i>BBS4</i>	<i>CPE</i>	<i>PLXNA3</i>
<i>BBS5</i>	<i>CREBBP</i>	<i>PLXNA4</i>
<i>BBS6 (MKKS)</i>	<i>DNMT3A</i>	<i>POMC</i>
<i>BBS7</i>	<i>HTR2C</i>	<i>RPGRIP1L</i>
<i>BBS8 (TTC8)</i>	<i>ISL1</i>	<i>SEMA3A</i>
<i>BBS9 (PTHB1)</i>	<i>KSR2</i>	<i>SEMA3B</i>
<i>BBS10</i>	<i>LEP</i>	<i>SEMA3C</i>
<i>BBS11 (TRIM32)</i>	<i>LEPR</i>	<i>SEMA3D</i>
<i>BBS12</i>	<i>MAGEL2</i>	<i>SEMA3E</i>
<i>BBS13 (MKS1)</i>	<i>MC3R</i>	<i>SEMA3F</i>
<i>BBS14 (CEP290)</i>	<i>MECP2</i>	<i>SEMA3G</i>
<i>BBS15 (WDPCP)</i>	<i>MRAP2</i>	<i>SH2B1</i>
<i>BBS16 (SDCCAG8)</i>	<i>NCOA1 (SRC1)</i>	<i>SIM1</i>
<i>BBS17 (LZTFL1)</i>	<i>NRP1</i>	<i>TBX3</i>
<i>BBS18 (BBIPI)</i>	<i>NRP2</i>	<i>TRPC5</i>
<i>BBS19 (IFT27)</i>	<i>PCSK1</i>	<i>TUB</i>
Category 2: genetic variants that may contribute to a diagnosis of genetic obesity but are neither currently indicated for setmelanotide treatment nor under investigation for setmelanotide efficacy in clinical trials.		
<i>ADCY3</i>	<i>GNAS</i>	<i>PPARG</i>
<i>AFF4</i>	<i>INPP5E</i>	<i>PROK2</i>
<i>ALMS1</i>	<i>KIDINS220</i>	<i>RAB23</i>
<i>BDNF</i>	<i>MC4R</i>	<i>RAI1</i>
<i>CUL4B</i>	<i>NR0B2</i>	<i>RPS6KA3</i>
<i>DYRK1B</i>	<i>NTRK2</i>	<i>UCP3</i>
<i>EP300</i>	<i>PCNT</i>	<i>VPS13B</i>
<i>GNAS</i>	<i>PHF6</i>	

Table S2. The genetic panel and risk assessments.

Gene	Gene name	Description (HGVS/ISCN)	Number detected	Zygosity	Classification (ACMG)
<i>AFF4</i>	ALF transcription elongation factor 4	NM_014423.4:c.455A>G p.(Asp152Gly)	1	Het.	VUS
<i>ALMS1</i>	ALMS1 centrosome and basal body associated protein	NM_015120.4:c.10775del p.(Thr3592Lysfs*6)	1	Het.	Pathogenic
		NM_001378454.1:c.3715_3718del p.(Ser1239fs)	1		Likely pathogenic
<i>ARMC5</i>	Armadillo repeat containing 5	NM_001105247.2:c.2597 C>T p.(Pro866Leu)	1	Het.	VUS
<i>BBS1</i>	Bardet-Biedl syndrome 1	NM_024649.5:c.1169T>G p.(Met390Arg)	2	Het.	Pathogenic
		NM_024649.5:c.1169T>G p.(Met390Arg)	1		
<i>BBS7</i>	Bardet-Biedl syndrome 7	NM_176824.3:c.1458C>G p.(Tyr486*)	2	Het.	VUS
		NM_176824.3:c.1876dup p.(Ile626Asnfs*2)	2		
<i>BBS9</i>	Bardet-Biedl syndrome 9	NM_198428.3:c.(442+1_443-1)_(702+1_703-1)del	1	Het.	Pathogenic
<i>CEP290</i>	Centrosomal protein 290	NM_025114.4:c.4966G>T p.(Glu1656*)	1	Het.	Pathogenic
		C.(102+1_103-1)_(495+1_496-1)del	1		VUS
<i>CREBBP</i>	CREB binding protein	NM_004380.3:c.2980G>A p.(Val994Met)	1	Het.	VUS
		NM_004380.3:c.4372T>A p.(Leu1458Ile)	1		
<i>CUL4B</i>	Cullin 4B	NM_003588.3:c.52A>G p.(Thr18Ala)	1	Hem.	VUS
<i>DNMT3A</i>	DNA methyltransferase 3 alpha	NM_175629.2:c.58G>A p.(Glu20Lys)	1	Het.	VUS
		NM_175629.2:c.856-10G>A p.?	1		

<i>DYRK1B</i>	Dual specificity tyrosine phosphorylation regulated kinase 1B	NM_004714.3:c.106G>C p.(Ala36Pro)	1	Het.	VUS
<i>EP300</i>	E1A binding protein P300	NM_001429.4:c.2572A>G p.(Thr858Ala)	1	Het.	VUS
		NM_001429.4:c.3568A>G p.(Thr1190Ala)	1		
		NM_001429.4:c.902A>C p.(Asn301Thr)	1		
		NM_001429.4:c.952C>G p.(Pro318Ala)	1		
<i>KIDINS220</i>	Kinase D interacting substrate 220	NM_020738.4:c.4925G>A p.(Arg1642Gln)	1	Het.	VUS
		NM_020738.4:c.3617T>C p.(Leu1206Ser)	1		
		NM_020738.4:c.(?_1-1) _108+1_109-1)del	1		
<i>MAGEL2</i>	MAGE family member L2	NM_019066.5:c.2635C>T p.(Pro879Ser)	1	Het.	VUS
		NM_019066.5:c.1375C>T p.(Arg459Cys)	1		
		NM_019066.5:c.2329C>A p.(Pro777Thr)	1		
		NM_019066.5:c.1586_160 6del p.(Ala529_Gln535del)	1		
<i>MC3R</i>	Melanocortin-3 receptor	NM_019888.3:c.452G>A p.(Arg151His)	1	Het.	VUS
		NM_019888.3:c.770C>A p.(Pro257His)	1		
<i>MC4R</i>	Melanocortin-4 receptor	NM_005912.3:c.598A>G p.(Met200Val)	1	Het.	VUS
		NM_005912.3:c.89C>T p.(Ser30Phe)	1		
<i>MECP2</i>	Methyl CpG binding protein 2	NM_004992.3:c.605C>G p.(Ala202Gly)	1	Het.	VUS
		NM_004992.3:c.1102C>T p.(His368Tyr)	1	Hem.	

<i>MRAP2</i>	Melanocortin 2 receptor accessory protein 2	NM_138409.4:c.389A>G p.(Lys130Arg)	1	Het.	VUS
<i>NCOA1</i>	Nuclear receptor coactivator 1	NM_003743.5:c.2365A>G p.(Thr789Ala)	1	Het.	VUS
<i>NRPI</i>	Neuropilin 1	NM_003873.7:c.259G>A p.(Val87Met)	1	Het.	VUS
<i>NRP2</i>	Neuropilin 2	NM_201266.2:c.2173G>C p.(Gly725Arg)	1	Het.	VUS
<i>NTRK2</i>	Neurotrophic receptor tyrosine kinase 2	C.(2172+1_2173-1)_(*1_?)dup	1	Het.	VUS
		NM_006180.5:c.1345G>A p.(Val449Ile)	1		
		NM_006180.5:c.809A>G p.(Asn270Ser)	1		
<i>PCNT</i>	Pericentrin	NM_006031.6:c.362_363del p.(Thr121Serfs*3)	1	Het.	Likely pathogenic
		NM_006031.6:c.4090G>T p.(Glu1364*)	1		
		NM_006031.6:c.2347dup p.(Gln783Profs*8)	2		
<i>PCSK1</i>	Proprotein convertase subtilisin kexin type 1	NM_000439.5:c.661A>G p.(Asn221Asp)	13	Het.	VUS
		NM_000439.5:c.2129C>G p.(Pro710Arg)	1		
		NM_000439.5:c.1096A>G p.(Thr366Ala)	1		
		NM_000439.5:c.1030G>A p.(Ala344Thr)	1		
		NM_000439.5:c.375G>A p.(Met125Ile)	2		
		NM_000439.4:c.1918A>G p.(Thr640Ala)	3		
<i>PHIP</i>	Pleckstrin homology domain interacting protein	NM_017934.7:c.3670C>G p.(Leu1224Val)	1	Het.	VUS
		NM_017934.7:c.2579G>A p.(Gly860Glu)	1		

		NM_017934.7:c.3628A>G p.(Lys1210Glu)	1		
<i>PLXNA1</i>	Plexin A1	NM_032242.4:c.989T>C p.(Leu330Pro)	1	Het.	VUS
		NM_032242.4:c.1309G>C p.(Val437Leu)	1		
		NM_032242.4:c.211A>G p.(Ile71Val)	1		
<i>PLXNA2</i>	Plexin A2	NM_025179.4:c.973G>A p.(Ala325Thr)	1	Het.	VUS
		NM_025179.4:c.5243G>T p.(Trp1748Leu)	1		
		NM_025179.4:c.5503G>A p.(Glu1835Lys)	1		
		NM_025179.4:c.2983G>A p.(Glu995Lys)	2		
		NM_025179.4:c.95C>G p.(Ala32Gly)	1		
		NM_025179.4:c.1423G>T p.(Val475Leu)	1		
		NM_025179.4:c.5251G>A p.(Val1751Met)	1		
<i>PLXNA3</i>	Plexin A3	NM_017514.5:c.139G>A p.(Val47Met)	1	Het.	VUS
		NM_017514.5:c.1048C>T p.(Arg350Trp)	1		
		NM_017514.5:c.1423A>G p.(Ile475Val)	1		
<i>PLXNA4</i>	Plexin A4	NM_020911.1:c.1259G>T p.(Arg420Leu)	1	Het.	VUS
		NM_020911.2:c.299T>A p.(Ile100Asn)	1		
		NM_020911.1:c.4903C>T p.(Arg1635Cys)	1		
		NM_020911.2:c.3492+3G >A p.?	1		
		NM_020911.2:c.1570G>A p.(Asp524Asn)	1		

<i>POMC</i>	Proopiomelanocortin	NM_001035256.2:c.706C>G p.(Arg236Gly)	5	Het.	Likely pathogenic
		NM_001035256.2:c.394C>G p. (Pro132Ala)	3		VUS
<i>PROK2</i>	Prokineticin 2	c.(222+1_223-1)_(*1_?)del	1	Het.	VUS
		NM_001126128.2:c.297dup p p.(Gly100Trpfs*22)	1		
<i>RAI1</i>	Retinoic Acid Induced 1	NM_030665.4:c.867_872dup p.(Gln290_Gln291dup)	1	Het.	VUS
		NM_030665.4:c.194C>T p.(Thr65Met)	1		
		NM_030665.4:c.864_872dup p.(Gln289_Gln291dup)	1		
		NM_030665.4:c.4996C>G p.(Leu1666Val)	1		
<i>RPGRIP1L</i>	RPGRIP1 like	NM_015272.5:c.2200C>T p.(Arg734*)	1	Het.	Likely pathogenic
		NM_015272.5:c.1489G>T p.(Glu497*)	1		
<i>RPS6KA3</i>	Ribosomal protein S6 kinase A3	c.(774+1_775-1)_ (1102+1_1103-1)del	1	Het.	Likely pathogenic
<i>SDCCAG8</i>	SHH signalling and ciliogenesis regulator SDCCAG8	NM_006642.5:c.696T>G p.(Tyr232*)	1	Het.	Likely pathogenic
<i>SEMA3A</i>	Semaphorin 3A	NM_006080.3:c.1799A>T p.(Lys600Met)	1	Het.	VUS
		NM_006080.3:c.458A>G p.(Asn153Ser)	1		
<i>SEMA3B</i>	Semaphorin 3B	NM_004636.2:c.1860G>C p.(Glu620Asp)	1	Het.	VUS
		NM_004636.2:c.586C>T p.(Arg196*)	1		
<i>SEMA3C</i>	Semaphorin 3C	NM_006379.5:c.857C>T p.(Ala286Val)	1	Het.	VUS
<i>SEMA3D</i>	Semaphorin 3D	NM_152754.3:c.113T>C p.(Leu38Ser)	1	Het.	VUS

<i>SEMA3 E</i>	Semaphorin 3E	NM_012431.3: c.283T>Gp.(Trp95Gly)	1	Het.	VUS
		NM_012431.3:c.214G>T p.(Val72Leu)	1		
		NM_012431.3:c.(115+1_1 16-1)_(336+1_337-1)del	1		
		NM_012431.3:c.1514T>C p.(Ile505Thr)	1		
<i>SEMA3 F</i>	Semaphorin 3F	NM_004186.5:c.533C>T p.(Pro178Leu)	1	Het.	VUS
		NM_004186.5:c.1352G>A p.(Arg451Gln)	1		
		NM_004186.5:c.1588- 3C>T p.?	1		
<i>SEMA3 G</i>	Semaphorin 3G	NM_020163.3:c.200G>A p.(Arg67Gln)	1	Het.	VUS
		NM_020163.3:c.1574dup p.(Tyr525*)	1		
<i>SH2B1</i>	SH2B adaptor protein 1	NM_001145795.2:c.2083 G>A p.(Val695Met)	1	Het.	VUS
<i>SIM1</i>	Single-minded homolog 1	NM_005068.3:c.390G>A p.(Pro130=)	2	Het.	VUS
		NM_005068.3:c.1720A>G p.(Met574Val)	1		
		NM_005068.3:c.2135C>T p.(Thr712Ile)	1		
		NM_005068.3:c.452T>G p.(Val151Gly)	1		
		NM_005068.3:c.383T>C p.(Ile128Thr)	1		
		NM_005068.3:c.1445C>G p.(Pro482Arg)	2		
<i>TRPC5</i>	Transient receptor potential channel 5	NM_012471.3:c.2212C>A p.(Leu738Ile)	3	Het.	VUS
<i>UCP3</i>	Uncoupling protein 3	NM_003356.4:c.370T>A p.(Cys124Ser)	1	Het.	VUS

		NM_003356.4:c.304G>A	1		
		p.(Val102Ile)			
		NM_003356.4:c.88G>A	1		
		p.(Val30Ile)			
<i>VPS13B</i>	Vacuolar protein sorting 13 homolog B	NM_017890.4:c.11695_11 698del p.(Ser3901Argfs*40)	1	Het.	Likely pathogenic
		NM_017890.4:c.8172+1G >A p.?	1		

HGVS/ISCN: Human Genome Variation Society/International System for human Cytogenetic Nomenclature; ACMG: American College of Medical Genetics and Genomics; VUS: variant of uncertain significance; Het: heterozygous; Hem: hemizygous.

Table S3. The prevalence of each genetic variant of uncertain significance among the positive cases.

Gene	Zygoty	Number detected	Percentage (%)
<i>AFF4</i>	Het.	1	0.7
<i>ARMC5</i>	Het.	1	0.7
<i>BBS7</i>	Het.	4	2.8
<i>CEP290</i>	Het.	1	0.7
<i>CREBBP</i>	Het.	2	1.4
<i>CUL4B</i>	Hem.	1	0.7
<i>DNMT3A</i>	Het.	2	1.4
<i>DYRK1B</i>	Het.	1	0.7
<i>EP300</i>	Het.	4	2.8
<i>KIDINS220</i>	Het.	3	2.1
<i>MAGEL2</i>	Het.	4	2.8
<i>MC3R</i>	Het.	2	1.4
<i>MC4R</i>	Het.	2	1.4
<i>MECP2</i>	Het.	1	0.7
	Hem.	1	0.7
<i>MRAP2</i>	Het.	1	0.7
<i>NCOA1</i>	Het.	1	0.7

<i>NRP1</i>	Het.	1	0.7
<i>NRP2</i>	Het.	1	0.7
<i>NTRK2</i>	Het.	3	2.1
<i>PCSK1</i>	Het.	21	14.9
<i>PHIP</i>	Het.	3	2.1
<i>PLXNA1</i>	Het.	3	2.1
<i>PLXNA2</i>	Het.	8	5.7
<i>PLXNA3</i>	Het.	3	2.1
<i>PLXNA4</i>	Het.	5	3.5
<i>POMC</i>	Het.	3	2.1
<i>PROK2</i>	Het.	2	1.4
<i>RAI1</i>	Het.	4	2.8
<i>SEMA3A</i>	Het.	2	1.4
<i>SEMA3B</i>	Het.	2	1.4
<i>SEMA3C</i>	Het.	1	0.7
<i>SEMA3D</i>	Het.	1	0.7
<i>SEMA3E</i>	Het.	4	2.8
<i>SEMA3F</i>	Het.	3	2.1
<i>SEMA3G</i>	Het.	2	1.4

<i>SH2B1</i>	Het.	1	0.7
<i>SIM1</i>	Het.	8	5.7
<i>TRPC5</i>	Het.	3	2.1
<i>UCP3</i>	Het.	3	2.1
Het: heterozygous; Hem: hemizygous.			